Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objectives of this study are to assess the safety and the percentage of subjects achieving a 12-week sustained virologic response, SVR12 [Hepatitis C Virus (HCV) ribonucleic acid (RNA) < lower limit of quantification (LLOQ) 12 weeks following treatment] of coformulated ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 with ribavirin (RBV) for 12 or 24 weeks in HCV genotype 1 (GT1)-infected adults with decompensated cirrhosis
Inclusion criteria
- Chronic Hepatitis C Infection